Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.
Nanomedicine (Lond)
; 8(5): 687-98, 2013 May.
Article
en En
| MEDLINE
| ID: mdl-23075285
ABSTRACT
AIM:
Two unexplored aspects for irinotecan and cisplatin (I&C) combination chemotherapy are actively targeting both drugs to a specific diseased cell type, and delivering both drugs on the same vehicle to ensure their synchronized entry into the cell at a well-defined ratio. In this work, the authors report the use of targeted polymeric nanoparticles (NPs) to coencapsulate and deliver I&C to cancer cells expressing the prostate-specific membrane antigen. MATERIALS &METHODS:
Targeted NPs were prepared in a single step by mixing four different precursors inside microfluidic devices.RESULTS:
I&C were encapsulated in 55-nm NPs and showed an eightfold increase in internalization by prostate-specific membrane antigen-expressing LNCaP cells compared with nontargeted NPs. NPs coencapsulating both drugs exhibited strong synergism in LNCaP cells with a combination index of 0.2.CONCLUSION:
The strategy of coencapsulating both I&C in a single NP targeted to a specific cell type could potentially be used to treat different types of cancer.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Próstata
/
Neoplasias de la Próstata
/
Camptotecina
/
Cisplatino
/
Sistemas de Liberación de Medicamentos
/
Nanopartículas
/
Antineoplásicos
Límite:
Humans
/
Male
Idioma:
En
Revista:
Nanomedicine (Lond)
Año:
2013
Tipo del documento:
Article
País de afiliación:
Estados Unidos